Royalty Report: Drugs, Therapeutic, Biotechnology – Collection: 7077

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Therapeutic
  • Biotechnology
  • Cancer
  • Pharmaceuticals
  • Surgical
  • Wound Care

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7077

License Grant
University grants Licensee a license to the Biological Materials in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory. The license is Exclusive, including the right to sublicense, in the Licensed Field of Use beginning on September 17, 2004, and ending on September 17, 2019.
License Property
Stanford has certain rights to biological material, specifically hybridoma cell lines known as K6H6/B5 and 1D12 .

Biological Materials means the K6H6/B5 and /or 1D12 cell lines.

Field of Use
Licensed Field of Use means the use of the Biological Materials to generate a series of personalized vaccines for the treatment of B and T cell neoplasms.

IPSCIO Record ID: 26654

License Grant
We entered into an agreement giving us worldwide rights to use two proprietary hybridoma cell lines that are used in the production of BiovaxID with the University. These are the same cell lines that have been used by researchers at Stanford and the National Cancer Institute to perform their studies of the hybridoma idiotype vaccine in non-Hodgkins lymphoma. This agreement gives us exclusive rights to these cell lines through 2019 in the fields of B-cell and T-cell cancers, and it gives us non-exclusive rights in such fields of use at all times after 2019. The agreement also gives us the right to sublicense or transfer the licensed biological materials to collaborators in the licensed fields.
License Property
Biovaxid is a randomized phase III vaccine clinical research study being conducted at several cancer centers and clinics in the United States to compare two types of vaccine treatments for people with Stage III or IV follicular lymphoma — a type of cancer in the lymph nodes.
Field of Use
The rights granted apply to the medical field, primarily to cancer.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

IPSCIO Record ID: 211863

License Grant
Licensor is the assignee of all right, title and interest in the Patent Rights, Biological Materials and Know-How from a third party.

Pursuant to the third partys permission, for the nonexclusive license, Licensor grants the worldwide, nonexclusive right and license, with the right to sublicense, in the Field under the Patent Rights to make, have made, use, lease, sell, offer for sale and import the Licensed Products and to practice the Licensed Processes; to make, have made, use, lease, sell, offer for sale, import and create Modifications of the Biological Materials; and to use Know-How, and

For the exclusive license, Licensor grants the worldwide, exclusive right and license, with the right to sublicense, in the Field to make, have made, use, lease, sell, offer for sale and import Modifications.

License Property
The licensed products include among other things, Progeny, an unmodified descendant from the Biological Materials, such as virus from virus, cell from cell, or organism from organism.   Some examples include subclones of unmodified cell lines, purified or fractionated subsets of the Biological Material(s), proteins expressed by DNA/RNA supplied by Licensor, or monoclonal antibodies secreted by a hybridoma cell line.
Field of Use
The Field shall mean IN VIVO human and veterinary medical use of polymers falling within the Patent Rights, including, without limitation, tissue engineering, cell therapy, implantables, medical devices, wound sealants, prescription and non-prescription drug delivery, and contrast agents, but excluding medical disposables, surgical drapes and trays, sanitary products, barrier contraceptives, nutritional and all other diagnostic uses and transgenic plant crop production of polymers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.